Open AccessThe anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination
Author(s) -
Robert J. Benschop,
Jay Tuttle,
Lin Zhang,
Josh Poorbaugh,
Nicole L. Kallewaard,
Peter Vaillancourt,
Melissa Crisp,
Thi Ngoc Vy Trinh,
Joshua J. Freitas,
Stephanie Beasley,
Montanea Daniels,
Natalie Haustrup,
Richard E. Higgs,
Ajay Nirula,
Myron S. Cohen,
Mary Marovich
Publication year - 2022
Publication title -
carolina digital repository (university of north carolina at chapel hill)
Language(s) - English
DOI - 10.17615/77w4-hz26
Subject(s) - covid-19 , virology , vaccination , monoclonal antibody , immune system , sars virus , betacoronavirus , antibody response , biology , coronavirus infections , endogeny , antibody , immunology , medicine , outbreak , infectious disease (medical specialty) , pathology , disease , endocrinology